SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-310715
Filing Date
2020-12-04
Accepted
2020-12-04 16:51:10
Documents
67
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d140358d10q.htm 10-Q 496351
2 EX-31.1 d140358dex311.htm EX-31.1 10447
3 EX-31.2 d140358dex312.htm EX-31.2 10377
4 EX-32.1 d140358dex321.htm EX-32.1 3396
5 EX-32.2 d140358dex322.htm EX-32.2 3272
  Complete submission text file 0001193125-20-310715.txt   3966040

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT fhtx-20200930.xml EX-101.INS 807449
7 XBRL TAXONOMY EXTENSION SCHEMA fhtx-20200930.xsd EX-101.SCH 40981
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fhtx-20200930_cal.xml EX-101.CAL 40837
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fhtx-20200930_def.xml EX-101.DEF 156239
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE fhtx-20200930_lab.xml EX-101.LAB 331038
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fhtx-20200930_pre.xml EX-101.PRE 268528
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39634 | Film No.: 201370424
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences